Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2006 / N 2

Место надропарина в арсенале антитромботической терапии терапевта и хирурга (Список литературы)
Е.П. Панченко, А.Л. Комаров

1. Fuster V., Fallon J.T., Badimon J.J., Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention Thrombosis and Hemostasis 1997, 78 (1), 247-255.
2. W. Ageno, A. G.G. Turpie. New advances in the management of acute coronary syndromes: Low-molecular-weight heparins. CMAJ 2002; 166(7):919-24.
3. McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41:250–257.
4. J. Hirsh. Heparin and Low-Molecular-Weight Heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S–203S.
5. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina/Non–ST-Segment Elevation. J Am Coll Cardiol 2000;36:970-1056.
6. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. .J Am Coll Cardiol. 1995 Aug;26(2):313-8.
7. FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20: 1553-62.
8. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease study (FRIC). Circulation 1997;96:61-68.
9. Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
11. С.В.Шалаев, М.Я.Руда, Н.А.Грацианский и др. Эффективность и безопасность низкомолекулярного гепарина надропарина в удвоенной концентрации, вводимого один раз в сутки, в сравнении со стандартным режимом дозирования надропарина при остром коронарном синдроме без подъема сегмента ST (результаты рандомизированного контролируемого исследования SAFRAX в России). Кардиоваскулярная терапия и профилактика 2004; 3 (1):40-45.
12. Лечение острых коронарных синдромов. Острый коронарный синдром без стойкого подъема сегмента ST. Рекомендации рабочей группы Европейского Кардиологического общества 2000г. Приложение к журналу Кардиология N 4, 2001.
13. Bassand JP, Berthe C, Bethencourt A, et al. Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study. Curr Med Res Opin. 2003;19(2):107-13.
14. Wong GC, Giugliano RP, Antman EM. Use of low-molecular weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331-42.
15. J J. Popma, P. Berger, E. M Ohman et al. Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:576S–599S.
16. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 © 2005 by the American College of Cardiology Foundation and the American Heart Association, Inc. Guidelines for Percutaneous Coronary Intervention). American College of Cardiology Web Site. Available at: http://www.acc.org/clinical/guidelines/percutaneous/update/index_rev.pdf.
17. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004. Available at www.acc.org/clinical/guidelines/stemi/index.pdf.
18. S A J Chamuleau, R J de Winter, M Levi, R Adams et al. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Heart 1998;80;35-39.
19. Adam M. Curylo, Kalina Kawecka-Jaszcz, Danuta Czarnecka et al. Nadroparin calcium in the treatment of acute myocardial infarction. Med Sci Monit, 1997; 3(5): 700-703.
20. Charbonnier B. Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study. Arch Mal Coeur Vaiss. 1997 Sep;90(9):1215-21.
21. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997;30:962-9.
22. William H. Geerts, Graham F. Pineo, John A. Heit, et al. Prevention of Venous Thromboembolism The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S–400S.
23. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162–1173.
24. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988; 208:227–240
25. ттт
26. Dolovich LR, Ginsberg JS, Douketis JD, et al. A metaanalysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181–188.
27. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996 May-Jun;26(3):127-39.
28. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000; 161:1109–1114.
29. Pezzuoli G, Neri Serneri GG, Settembrini PG, et al. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group. Haemostasis. 1990;20 Suppl 1:193-204.
30. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg. 1985 Oct;72(10):786-91.
31. The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1988 Nov;75(11):1058-63.
32. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303:543–548
33. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Haemostasis. 1993 Mar;23 Suppl 1:20-6.
34. Haentjens P. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury. 1997 Apr;28(3):233-4.
35. Ninet J., Duroux P. A randomized trial of subcutaneous low molecular weight heparin compared with intravenous unfractionated heparin in the treatment of DVT. A collaborative European multicentre study. Thromb Haemost 1991; 65:251-5.
36. Prandoni P., Laesing A., Buller H et al. comparison of subcutaneous low molecular weight heparin with intravenous standart heparin in the treatment of proximal deep vein thrombosis. Lancet 1992; 339:441-5.
37. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 2001; 30:195–204
38. Schellong SM, Schwarz T, Kropp J, et al. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb Haemost 1999; 82(suppl): 127–129
39. Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost 2001; 85:42–46
40. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000; 32:861–869
41. M. Koopman, P. Prandoni, F. Piovella et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous lowmolecular-weight heparin administered at home. N Engl J Med 1996; 334:682-7.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]